LBPH
Longboard Pharmaceuticals, Inc. [LBPH] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
LBPH Stock Summary
In the News
LBPH Financial details
Company Rating
-
Market Cap
691.53M
Income
-53.92M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
50
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-11.07
Forward P/E
-
PEG
19.85
P/S
-
P/B
10.61
P/C
-
P/FCF
-11.32
Quick Ratio
8.35
Current Ratio
8.69
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.37
EPS next Y
-
EPS next Q
-
EPS this Y
-4.78%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
14.55%
-
-
-
-
SMA20
0.38%
SMA50
76.26%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-85%
ROE
-82%
ROC
-1.01%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.6-28.15
52W High
+114.21%
52W Low
+1899.33%
RSI
80.27
Rel Volume
-
Avg Volume
618.07K
Volume
Perf Week
0%
Perf Month
0.44%
Perf Quarter
-
Perf Half Y
67.78%
-
-
-
-
Beta
1.255
-
-
Volatility
0%, 0.13%
Prev Close
0%
Price
59.98
Change
0%
Company Profile
- Volume Average 618.07K
- Market Capitalization 691.53M
- Employee 50
- CEO Mr. Kevin R. Lind
- Headquarters La Jolla,CA,US
- IPO Date 2021-03-12
-
Website
https://www.longboardpharma.com 
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
